These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 11703321

  • 1. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?
    Spaepen K, Stroobants S, Dupont P, Thomas J, Vandenberghe P, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G.
    Br J Haematol; 2001 Nov; 115(2):272-8. PubMed ID: 11703321
    [Abstract] [Full Text] [Related]

  • 2. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
    Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, Vanuytsel L, Bormans G, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G.
    J Clin Oncol; 2001 Jan 15; 19(2):414-9. PubMed ID: 11208833
    [Abstract] [Full Text] [Related]

  • 3. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation.
    Guay C, Lépine M, Verreault J, Bénard F.
    J Nucl Med; 2003 Aug 15; 44(8):1225-31. PubMed ID: 12902411
    [Abstract] [Full Text] [Related]

  • 4. Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.
    Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G.
    Ann Oncol; 2002 Sep 15; 13(9):1356-63. PubMed ID: 12196360
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
    Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ.
    J Nucl Med; 2002 Aug 15; 43(8):1018-27. PubMed ID: 12163626
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.
    Cremerius U, Fabry U, Neuerburg J, Zimny M, Bares R, Osieka R, Büll U.
    Nuklearmedizin; 2001 Feb 15; 40(1):23-30. PubMed ID: 11373935
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W, Zhao J, Wang C, Wang T, Xing Y.
    Hematology; 2010 Feb 15; 15(1):21-7. PubMed ID: 20132658
    [Abstract] [Full Text] [Related]

  • 13. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
    Kobe C, Kuhnert G, Kahraman D, Haverkamp H, Eich HT, Franke M, Persigehl T, Klutmann S, Amthauer H, Bockisch A, Kluge R, Wolf HH, Maintz D, Fuchs M, Borchmann P, Diehl V, Drzezga A, Engert A, Dietlein M.
    J Clin Oncol; 2014 Jun 10; 32(17):1776-81. PubMed ID: 24799482
    [Abstract] [Full Text] [Related]

  • 14. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
    Reinhardt MJ, Herkel C, Altehoefer C, Finke J, Moser E.
    Ann Oncol; 2005 Sep 10; 16(9):1524-9. PubMed ID: 15946979
    [Abstract] [Full Text] [Related]

  • 15. Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up?
    Petrausch U, Samaras P, Veit-Haibach P, Tschopp A, Soyka JD, Knuth A, Hany TF, Mischo A, Renner C, Schaefer NG.
    Ann Oncol; 2010 May 10; 21(5):1053-7. PubMed ID: 19914963
    [Abstract] [Full Text] [Related]

  • 16. Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT.
    Akhtar S, Al-Sugair AS, Abouzied M, Alkadhi Y, Dingle M, Abdelsalam M, Soudy H, Darwish A, Eltigani A, Elhassan TA, Nabil-Ahmed M, Maghfoor I.
    Bone Marrow Transplant; 2013 Nov 10; 48(12):1530-6. PubMed ID: 23749108
    [Abstract] [Full Text] [Related]

  • 17. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
    Torizuka T, Nakamura F, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, Kobayashi M, Ouchi Y.
    Eur J Nucl Med Mol Imaging; 2004 Jan 10; 31(1):22-8. PubMed ID: 14574514
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma.
    Naumann R, Vaic A, Beuthien-Baumann B, Bredow J, Kropp J, Kittner T, Franke WG, Ehninger G.
    Br J Haematol; 2001 Dec 10; 115(4):793-800. PubMed ID: 11843811
    [Abstract] [Full Text] [Related]

  • 20. Pediatric Hodgkin Lymphoma: Predictive value of interim 18F-FDG PET/CT in therapy response assessment.
    Ferrari C, Niccoli Asabella A, Merenda N, Altini C, Fanelli M, Muggeo P, De Leonardis F, Perillo T, Santoro N, Rubini G.
    Medicine (Baltimore); 2017 Feb 10; 96(5):e5973. PubMed ID: 28151888
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.